United-Guardian Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $7.54
- Today's High:
- $7.6201
- Open Price:
- $7.54
- 52W Low:
- $7.1551
- 52W High:
- $14.0825
- Prev. Close:
- $7.61
- Volume:
- 2082
Company Statistics
- Market Cap.:
- $34.96 million
- Book Value:
- 2.282
- Revenue TTM:
- $10.40 million
- Operating Margin TTM:
- 25.8%
- Gross Profit TTM:
- $6.70 million
- Profit Margin:
- 21.56%
- Return on Assets TTM:
- 14.24%
- Return on Equity TTM:
- 22.25%
Company Profile
United-Guardian Inc had its IPO on 1992-03-17 under the ticker symbol UG.
The company operates in the Consumer Defensive sector and Household & Personal Products industry. United-Guardian Inc has a staff strength of 23 employees.
Stock update
Shares of United-Guardian Inc opened at $7.54 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $7.54 - $7.62, and closed at $7.62.
This is a +0.13% increase from the previous day's closing price.
A total volume of 2,082 shares were traded at the close of the day’s session.
In the last one week, shares of United-Guardian Inc have slipped by -4.75%.
United-Guardian Inc's Key Ratios
United-Guardian Inc has a market cap of $34.96 million, indicating a price to book ratio of 5.1718 and a price to sales ratio of 3.7237.
In the last 12-months United-Guardian Inc’s revenue was $10.40 million with a gross profit of $6.70 million and an EBITDA of $2.80 million. The EBITDA ratio measures United-Guardian Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, United-Guardian Inc’s operating margin was 25.8% while its return on assets stood at 14.24% with a return of equity of 22.25%.
In Q2, United-Guardian Inc’s quarterly earnings growth was a negative -27.2% while revenue growth was a negative 26.9%.
United-Guardian Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 15.8542
- PEG
- 0
Its diluted EPS in the last 12-months stands at $0.48 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into United-Guardian Inc’s profitability.
United-Guardian Inc stock is trading at a EV to sales ratio of 3.2821 and a EV to EBITDA ratio of 9.1247. Its price to sales ratio in the trailing 12-months stood at 3.7237.
United-Guardian Inc stock pays annual dividends of $0.41 per share, indicating a yield of 5.28% and a payout ratio of 83.64%.
Balance sheet and cash flow metrics
- Total Assets
- $11.88 million
- Total Liabilities
- $1.35 million
- Operating Cash Flow
- $4.85 million
- Capital Expenditure
- $1330
- Dividend Payout Ratio
- 83.64%
United-Guardian Inc ended 2024 with $11.88 million in total assets and $0 in total liabilities. Its intangible assets were valued at $11.88 million while shareholder equity stood at $10.48 million.
United-Guardian Inc ended 2024 with $0 in deferred long-term liabilities, $1.35 million in other current liabilities, 459432.00 in common stock, $10.02 million in retained earnings and $0 in goodwill. Its cash balance stood at $6.48 million and cash and short-term investments were $7.42 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
United-Guardian Inc’s total current assets stands at $11.36 million while long-term investments were $0 and short-term investments were $939576.00. Its net receivables were $1.54 million compared to accounts payable of $155842.00 and inventory worth $1.78 million.
In 2024, United-Guardian Inc's operating cash flow was $4.85 million while its capital expenditure stood at $1330.
Comparatively, United-Guardian Inc paid $0.84 in dividends in 2024.
Other key metrics
- Current Trading Price
- $7.62
- 52-Week High
- $14.0825
- 52-Week Low
- $7.1551
- Analyst Target Price
- $
United-Guardian Inc stock is currently trading at $7.62 per share. It touched a 52-week high of $14.0825 and a 52-week low of $14.0825. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $7.82 and 200-day moving average was $9.51 The short ratio stood at 0.71 indicating a short percent outstanding of 0%.
Around 3638.6% of the company’s stock are held by insiders while 2244.2% are held by institutions.
Frequently Asked Questions About United-Guardian Inc
Similar Industry Stocks (Household & Personal Products)
Most Active
Top Gainers
Top Losers
About
United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally The company offers cosmetic ingredients, including LUBRAJEL, a line of water-based gel formulation for sensory enhancement, lubrication, and texture to personal care products; LUBRAJEL NATURAL for skin moisturizing; LUBRAJEL MARINE that develops natural products using naturally derived polymers; LUBRAJEL OlL NATURAL, which makes luxuriant textures without adding viscosity; LUBRAJEL TERRA, a multifunctional, moisturizing hydrogel products; LUBRASIL II SB, a formulation of LUBRAJEL; LUBRAJEL II XD; B-122, a powdered lubricant used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; and ORCHID COMPLEX, an oil-soluble base for extract of fresh orchids used in fragrance products, such as perfumes and toiletries. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL MGL, a medical lubricant with a lower viscosity medical lubricant; LUBRAJEL LC, LUBRAJEL BA, and LUBRAJEL FA, which are formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company’s pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial used in urology. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and product development of cosmetic ingredients. The company was founded in 1942 and is based in Hauppauge, New York.